

Recommendations from York and Scarborough Medicines Commissioning Committee December 2015

Drug name	Indication	Recommendation	Rationale for recommendation	Place in therapy	RAG status	Potential full year cost impact
Tolvaptan (Jinarc®)	Autosomal dominant polycystic kidney disease	Approved	NICE TA 358 recommends recommended as an option for treating autosomal dominant polycystic kidney disease in adults to slow the progression of cyst development and renal insufficiency.	As per NICE criteria.	Red – specialist use only	£189,000 There is a PAS which is commercial in confidence.
Apremilast (Otezla®)	Adults with moderate to severe chronic plaque psoriasis	Not approved for use	NICE TA 368 does not support the use of this drug within its licensed indication.	Not routinely commissioned for this indication.	Black	Zero
Alogliptin (Vipidia®)	Type 2 diabetes	Approved	Lowest cost DPP-4 inhibitor with no significant differences across the class of drugs.	Recommended as 1 st line within its class when used within its license as per NICE guidance.	Green	Savings expected to be >£65 per patient per year.
Ondansetron 4mg tablets	Diarrhoea +/- nausea associated with irritable bowel disease	Approved	Small cohort of patients who are currently receiving therapy with this treatment. Only ondansetron 4mg	Patients would have been seen in primary care and worked through NICE guidance on IBS. If patients had not been offered a	Amber – specialist recommendation	26 patients over 12 months across York & Scarborough

	(unlicensed)		tablets were approved. The liquid and injection formulation were not supported for use.	tricyclic antidepressant this may be tried first, but not always as depends upon predominant symptoms and would be discontinued if no response.		= £1,609 based on median dosage of 4mg daily.
--	--------------	--	---	---	--	---

Other items

- TEWV shared care guidance - Melatonin for Sleep Disorders in Children, Young People and Adults
- TEWV Guidance for GPs - Smoking Cessation and Medicines Safety Concerns
- Dental requests for GPs to prescribe - GPs should not be prescribing dental products when a dentist could reasonably be expected to do so.